Novus Biologicals Announces New PAR1 Antibody

Littleton, CO, October 26, 2011 --(PR.com)-- Novus Biologicals announced today a new Thrombin Receptor antibody (catalog number NBP1-71770) for use in wound healing and cancer research.

Thrombin Receptor, also known as Protease activated receptor 1 (PAR1), is a G-protein-coupled receptor that functions in blood clotting. While Thrombin Receptor is known to have important functions in wound healing by inducing human platelet recruitment during thrombosis, it is also highly expressed in invasive and deadly cancers. Functionally, Thrombin Receptor is known to interact with FAK to alter endothelial barriers that normally inhibit cell proliferation across boundaries. It is thought that this relationship may account for the many metastatic effects associated with Thrombin Receptor.

Novus’ new Thrombin Receptor antibody (NBP1-71770) has been thoroughly characterized in ELISA, Western blot and immunostaining on human and mouse samples, with testing data available on the product datasheet. Additionally, this antibody has already been cited in a published article.

About Novus Biologicals (www.novusbio.com)

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

###